Nutra Pharma Corp (NPHC) Convertible Debt (2014 - 2026)

Nutra Pharma has disclosed Convertible Debt across 11 years of filings, most recently posting $2.4 million for Q2 2026.

• In Q2 2026, Convertible Debt changed N/A year-over-year to $2.4 million; the TTM figure through Jun 2026 stood at $2.4 million (changed N/A YoY), while the FY2025 annual figure was $1.1 million, changed N/A from the prior year.
• Convertible Debt came in at $2.4 million for Q2 2026 at Nutra Pharma, up from $1.1 million in the prior quarter.
• In the past five years, Convertible Debt ranged from a high of $2.4 million in Q2 2026 to a low of $1820.0 in Q4 2022.
• Average Convertible Debt over 4 years is $396349.7, with a median of $71106.5 recorded in 2022.
• Year-over-year, Convertible Debt plunged 99.51% in 2022 and surged 262.64% in 2023.
• Over 4 years, Convertible Debt stood at $1820.0 in 2022, then surged by 262.64% to $6600.0 in 2023, then soared by 17223.02% to $1.1 million in 2025, then surged by 111.45% to $2.4 million in 2026.
• Per Business Quant data, the three most recent Convertible Debt figures were $2.4 million in Q2 2026, $1.1 million in Q4 2025, and $6600.0 in Q4 2023.